Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study
在程序性死亡受体1阻断耐药的黑色素瘤患者中,瘤内注射维杜托利莫德作为单药治疗或与帕博利珠单抗联合治疗:一项1b期研究的最终分析
期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.70022
Milhem, Mohammed M; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth I; Medina, Theresa; Daud, Adil; Ribas, Antoni; Chmielowski, Bartosz; Niu, Jiaxin; Gibney, Geoffrey T; Margolin, Kim; Olszanski, Anthony J; Mehmi, Inderjit; Sato, Takami; Shaheen, Montaser; Zhao, Luping; Kelley, Heather; Liu, Hong; Kumar, Sujatha; Bobilev, Dmitri; Krieg, Arthur M; Wooldridge, James E; Kirkwood, John M